GlassScriptPhysician profile
Mary R Ramirez
NPI 1841686987
$11,360.55
in general payments reported to CMS, 2019-2025
34 companies · $2,163 in 2025
The $2,163 reported for 2025 was more than what 78% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $473 · 2021: $874 · 2022: $1,212 · 2023: $2,489 · 2024: $3,882 · 2025: $2,163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,073 · Education: $461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,072.65 |
| Education | $461.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $1,553.90 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Abbvie INC. | $1,543.15 | 2021-2025 | |
| Janssen Biotech, INC. | $1,008.78 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $937.15 | 2019-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $672.42 | 2023-2024 | Vtama |
| Incyte Corporation | $642.22 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $603.65 | 2020-2025 | Olumiant, Taltz, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $567.69 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $445.96 | 2021-2025 | |
| Leo Pharma INC. | $374.53 | 2019-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $309.92 | 2019-2025 | |
| Pfizer INC. | $279.03 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $257.65 | 2023-2025 | Zoryve |
| Revance Therapeutics, INC. | $256.60 | 2025 | Daxi, Daxxify |
| Ucb, INC. | $236.27 | 2023-2025 | Bimzelx, Cimzia |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $195.53 | 2021-2025 | Absorica Ld, Winlevi |
| Almirall LLC | $189.62 | 2021-2023 | Seysara |
| Krystal Biotech INC | $173.60 | 2023-2024 | Vyjuvek |
| Organon LLC | $170.81 | 2025 | Vtama |
| Nobelpharma America, LLC | $139.60 | 2024 | |
| Amgen INC. | $129.45 | 2021-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $124.43 | 2019-2025 | Jublia |
| Allergan, INC. | $116.33 | 2020-2022 | |
| Biofrontera INC. | $75.61 | 2022-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Sanofi-Aventis U.S. LLC | $72.00 | 2022 | |
| Fresenius Kabi USA, LLC | $71.34 | 2023-2024 | Idacio |
| Organogenesis INC. | $43.57 | 2025 | Simplimax |
| Pierre Fabre Pharmaceuticals, INC. | $39.38 | 2023 | Hemangeol |
| Vyne Pharmaceuticals INC. | $34.38 | 2020-2021 | |
| Merz North America, INC. | $34.17 | 2019 | |
| Medimetriks Pharmaceuticals, INC. | $22.42 | 2021 | |
| Lnhc, INC | $15.73 | 2025 | Zelsuvmi |
| Journey Medical Corporation | $12.98 | 2022 | |
| Kerecis Limited | $10.68 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.